GN
GNMSF.US Genmab A/S
- Market cap
- USD 31.4B
- P/E
- 43.5x
- P/B
- 4.96x
- ROE
- 14.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GNMSF.US undervalued?
Graham numberThe Graham number of Genmab A/S cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genmab A/S fundamental analysis
No fundamental analysis for Genmab A/S yet.
Genmab A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…
Full company profileGenmab A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genmab A/S annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.82B | 2.37B | 3.03B | 5.37B | 10.1B | 8.48B | 14.5B | 16.5B | 21.5B | 3.85B | 4.29B |
| Gross Profit | 1.82B | 2.37B | 3.03B | 5.37B | 10.1B | 8.42B | 14.5B | 16.2B | 20.5B | 3.53B | 3.97B |
| Operating Income | 1.05B | 1.34B | 1.38B | 2.64B | 6.31B | 2.95B | 6.27B | 5.32B | 6.98B | 1.29B | 1.41B |
| EBITDA | 1.17B | 1.12B | 1.70B | 3.01B | 6.17B | 3.27B | 7.33B | 5.99B | 9.70B | 1.37B | 1.47B |
| Net Income | 1.19B | 1.10B | 1.47B | 2.17B | 4.76B | 2.96B | 5.45B | 4.35B | 7.84B | 997M | 922M |
| EPS | 19 | 18 | 24 | 34 | 72 | 45 | 83 | 66 | 121 | 16 | 15 |
| Balance Sheet | |||||||||||
| Total Assets | 5.24B | 6.60B | 8.46B | 15.1B | 21.1B | 24.6B | 30.1B | 35.3B | 45.8B | 12.8B | 12.9B |
| Total Liabilities | 412M | 331M | 447M | 1.10B | 2.02B | 2.43B | 2.84B | 3.68B | 9.11B | 6.99B | 6.60B |
| Shareholders' Equity | 4.83B | 6.27B | 8.01B | 14.0B | 19.1B | 22.2B | 27.3B | 31.6B | 36.7B | 5.82B | 6.33B |
| Cash & Short-term Investments | 3.92B | 5.42B | 6.11B | 11.0B | 16.1B | 19.3B | 22.3B | 28.1B | 21.1B | 1.71B | 1.86B |
| Total Debt | 0.00 | 0.00 | 0.00 | 181M | 319M | 425M | 597M | 770M | 1.03B | 5.54B | 5.20B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 328M | 1.59B | 1.01B | 1.33B | 6.43B | 2.23B | 3.91B | 7.38B | 7.77B | 1.23B | 764M |
| Capital Expenditure | 33.1M | 88.5M | 477M | 111M | 307M | 252M | 317M | 376M | 187M | 38.3M | 23.9M |
| Free Cash Flow | 295M | 1.50B | 537M | 1.22B | 6.13B | 1.98B | 3.60B | 7.00B | 7.58B | 1.19B | 740M |
| Ratios | |||||||||||
| ROE | 24.6% | 17.6% | 18.4% | 15.4% | 24.9% | 13.3% | 20.0% | 13.8% | 21.4% | 17.1% | 14.6% |
| ROA | 22.7% | 16.7% | 17.4% | 14.3% | 22.5% | 12.0% | 18.1% | 12.3% | 17.1% | 7.8% | 7.1% |
| Net Profit Margin | 65.4% | 46.7% | 48.7% | 40.4% | 47.1% | 34.9% | 37.6% | 26.4% | 36.4% | 25.9% | 21.5% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.02x | 0.02x | 0.02x | 0.02x | 0.03x | 0.95x | 0.82x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genmab A/S dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | DKK 280M | 4.24 | 5.1% |
| 2021 | DKK 135M | 2.04 | 4.6% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Genmab A/S
- Insiders 1.12%
- Institutions 46.41%
- Public & others 52.47%
- Shares outstanding 61.7M
- Free float 58.9M
Genmab A/S company profile
- Company name
- Genmab A/S
- Ticker
- GNMSF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,244
- Fiscal year end
- December
- Address
- Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
- Phone
- 45 70 20 27 28
- Website
- genmab.com
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Genmab A/S management
10- Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO · born 1961
- Mr. Anthony Pagano CPAExecutive VP & CFO · born 1978
- Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer · born 1968
- Mr. Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer · born 1971
- Mr. Christopher CozicExecutive VP & Chief People Officer · born 1978
- Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer · born 1971
- Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director · born 1975
- Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer · born 1958
- Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines · born 1973
- Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director · born 1973